Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 33%
Hold 33%
Sell 8%
Strong Sell 0%

Bulls say

CME Group reports a total revenue of $1,649 million, reflecting an 8.1% year-over-year growth, driven by strong demand in its Market Data segment, which grew by 14.5% in the same period. The company has demonstrated robust free cash flow generation, which has allowed it to increase its quarterly dividend payments consistently for over 14 years. Additionally, CME has achieved a compound annual growth rate of approximately 7%+ in average daily volume (ADV) from FY16 through FY24, indicating a solid trend in customer demand and product innovation.

Bears say

CME Group faces significant challenges due to heightened competitive pressures from emerging market entrants, particularly FMX, which are expected to adversely affect trading volumes in interest rate futures amid an anticipated rate-cutting cycle. The company's projected revenue growth of approximately 5.4% year-over-year falls short of the consensus estimate of 6.0%, signaling potential struggles in achieving revenue targets and raising concerns about future profitability. Additionally, management has acknowledged difficulties in distinguishing Google-related expenses from baseline technology spending, which may obscure financial clarity and impact operational efficiency moving forward.

CME Group (CME) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 12 analysts, CME Group (CME) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $310.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $310.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.